ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing
ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing
ArcticZymes Technologies Announces Commercial Strategic Transformation and Q3 2024 Financial Results
Tromsø, Norway, November 6th, 2024 – ArcticZymes Technologies (OSE: AZT) reported revenues of NOK 24.1 million and an EBITDA of NOK -2.3 million for the third quarter of 2024.
ArcticZymes Highlights Industry-Leading Success at ESGCT 2024
ArcticZymes Technologies ASA (OSE: AZT), a global leader in enzyme innovation for bioprocessing, is excited to unveil breakthrough developments presented at the prestigious European Society of Gene and Cell Therapy (ESGCT) 2024 conference
Research Paper About Novel RNA Restriction Enzyme Published in Journal: Nucleic Acids Research
ArcticZymes Technologies ASA Publishes Innovative Research on Novel RNA Restriction Enzyme, Paving the Way for Precision RNA Manipulation
ArcticZymes Technologies Q2 and 6M 2024 Results – Progress in partnership discussions and portfolio development
Tromsø, Norway, Aug 22, 2024 – ArcticZymes Technologies (OSE: AZT) reported revenues of NOK 27.5 million and an EBITDA of NOK 2.6 million for the second quarter of 2024.